STACKD summary
EmergingThymalin and thymosin alpha-1: thymic peptides for immune support
One is a Zadaxin-branded drug approved in 35+ countries; the other is single-institute Russian research that's never been independently replicated.
Plain-language summary
Thymalin and thymosin alpha-1 both come out of thymus-tissue research aimed at supporting immune function as the thymus gland naturally shrinks with age. But their evidence bases are not close to equivalent. Thymosin alpha-1 is a single, well-defined peptide sold internationally as Zadaxin/thymalfasin, approved in more than 35 countries for chronic hepatitis B, with randomized controlled trial data behind it. Thymalin is a mixture of multiple peptides extracted from calf thymus, developed by one Russian research institute, with a much thinner and entirely open-label evidence base that has never been independently replicated outside that group.
What was studied
For thymosin alpha-1: randomized trials in chronic hepatitis B, alone and combined with interferon, plus a 120-patient RCT in HBV-related acute-on-chronic liver failure measuring transplant-free survival. For thymalin: a long-running open-label observational study following 266 elderly people for 6 to 8 years, plus a more recent exploratory study in hospitalized elderly COVID-19 patients.
Key takeaways
- Thymosin alpha-1 is one of the few peptides in this space with genuine randomized controlled trial data and real international drug approval, just not in the United States, where it's only available through 503A compounding pharmacies.
- Thymalin's most-cited finding, a roughly two-fold lower mortality rate in an elderly cohort given periodic courses over 6 to 8 years, comes from an open-label, single-institute study without blinded cause-of-death adjudication.
- Both peptides are proposed to work by supporting T-cell maturation and immune competence, but thymosin alpha-1 is a single, precisely characterized 28-amino-acid peptide, while thymalin is an unstandardized mixture extracted from animal tissue.
- Neither peptide's strongest data comes from healthy people using it for general immune optimization; thymosin alpha-1's trials are in hepatitis and liver-failure patients, and thymalin's are in elderly cohorts and hospitalized COVID-19 patients.
Limitations & what we don't know
- Thymalin's evidence comes overwhelmingly from one research institute using open-label designs, a meaningfully weaker standard than the blinded, multi-site trials expected for regulatory approval elsewhere.
- Thymosin alpha-1's response rates in some hepatitis trials were moderate, around 50 percent, and it is not FDA-approved as a prescription drug in the US.
- As a peptide mixture rather than a single synthesized compound, thymalin's batch-to-batch composition is inherently less standardized than thymosin alpha-1's.
- Neither peptide has trial data specific to healthy adults seeking general immune or longevity benefits, which is how both are frequently marketed.
Sources
Primary citations behind this summary. External links are provided for verification, read them yourself before drawing conclusions.